Impact of JN.1 booster vaccination on neutralisation of SARS-CoV-2 variants KP.3.1.1 and XEC
Preprint
Abstract
The SARS-CoV-2 KP.3.1.1 lineage is currently the dominating lineage on several continents. In parallel, the XEC lineage, a recombinant of KS.1.1 and KP.3.3, is on track of becoming the next dominant lineage in Europe and North America. Here we performed a rapid virological characterisation of the XEC lineage and studied the impact of JN.1 mRNA booster vaccination on KP.3.1.1 and XEC neutralisation.Keywords
All Related Versions
- Published version: The Lancet Infectious Diseases, 24 (12), e732.
This publication has 2 references indexed in Scilit:
- Humoral immunity after mRNA SARS-CoV-2 omicron JN.1 vaccinationThe Lancet Infectious Diseases, 2024
- Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric virusesJournal of Experimental Medicine, 2020